Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
US11193114B2 · kind B2 · utility
2Cited by
22References
15Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 14, 2018 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | Nov 28, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10334
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention describes new peptides containing epitopes recognized by CD4+ natural killer T (NKT) cells for increasing activity for use in infectious diseases, autoimmune diseases, immune reaction to administration of allofactors, allergic diseases, therapy of tumors, prevention of graft rejection and prevention of immunization against viral proteins used in gene therapy or gene vaccination.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.